Form 4: Astrana Health CMO Disposes Shares for Tax Obligations

Astrana Health's Chief Medical Officer, Dinesh M. Kumar, disposed of 10,759 shares to cover tax obligations related to restricted stock vesting.

Summary

• Dinesh M. Kumar, Chief Medical Officer of Astrana Health, Inc. (ASTH), reported a transaction on January 23, 2026.
• The transaction involved the disposition of 10,759 shares of common stock at a price of $27.16 per share.
• This disposition was a surrender of shares to offset tax withholding obligations associated with the vesting of restricted stock.
• Following this transaction, Mr. Kumar beneficially owns 202,032 shares of common stock directly.
• The remaining beneficial ownership includes 28,378 restricted shares vesting on January 23, 2027, and performance-based grants of 8,158 and 3,264 restricted shares.
• Also included are 67,238 performance-based restricted stock units (RSUs) and 23,364 RSUs vesting in seven equal semi-annual installments starting March 5, 2026.
• The total beneficial ownership also includes 1,405 shares acquired under the Issuer's Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shares were disposed, it was for a routine tax obligation related to the vesting of equity, which is a positive event for the executive. The executive retains substantial beneficial ownership, indicating continued alignment.

Positives

• The vesting of restricted stock indicates the achievement of prior performance milestones or continued service by the Chief Medical Officer.
• The executive maintains a substantial beneficial ownership of 202,032 shares, demonstrating continued alignment with shareholder interests.

Negatives

• The disposition of shares, while for tax purposes, reduces the direct beneficial ownership of the Chief Medical Officer.

Future Outlook

The filing indicates future vesting schedules for a significant number of restricted shares and restricted stock units through at least January 2027 and beyond, subject to continuous employment and achievement of performance goals, suggesting ongoing executive commitment and future equity compensation.

Management Comments

• The filing was signed by Kathy Diep as Attorney-in-Fact for Dinesh M. Kumar.

Industry Context

This Form 4 filing details a routine insider transaction common in executive compensation structures across various industries. The surrender of shares for tax withholding upon restricted stock vesting is a standard practice and does not typically reflect a change in the company's operational performance or strategic direction.

Comparison to Industry Standards

• The practice of surrendering shares to cover tax obligations upon the vesting of restricted stock or RSUs is a standard and widely accepted method of managing equity compensation in publicly traded companies, consistent with practices at peers in the healthcare services sector.
• The continued significant beneficial ownership by the Chief Medical Officer, including substantial unvested equity, aligns with typical executive incentive structures designed to promote long-term alignment with shareholder interests, comparable to executives at companies like UnitedHealth Group or CVS Health, which also utilize performance-based equity.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related transaction and does not reflect a change in company fundamentals or executive confidence.
• Employees: No direct impact mentioned beyond the executive's compensation.

Next Steps

• Continued vesting of 28,378 restricted shares on January 23, 2027.
• Ongoing vesting of 8,158 and 3,264 performance-based restricted shares.
• Ongoing vesting of 67,238 performance-based restricted stock units.
• Continued semi-annual vesting of 23,364 restricted stock units starting March 5, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the Chief Medical Officer disposed of shares solely to cover tax obligations upon the vesting of restricted stock. It does not indicate a change in the company's operational performance, strategic direction, or the executive's long-term confidence in the company. Therefore, it provides no new information that would warrant a change in investment recommendation.

Keywords

Astrana Health, ASTH, Form 4, Insider Transaction, Stock Vesting, Tax Withholding, Dinesh M. Kumar, Chief Medical Officer, Restricted Stock Units